Cerus Corp (CERS) — Analysis Summary
Cerus Corp (CERS) has a market cap of $513.89M with year-over-year revenue growth of +16.1%. Net margin stands at -6.7%. The stock trades at a P/E ratio of -75.8.
Key Takeaways
- Revenue changed +16.1% year-over-year
- Net margin of -6.7%
- P/E ratio of -75.8
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, CERS posted revenue growth of +16.1% and trades at a P/E of -75.8.
Cerus Corp (CERS)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 986.2x — highly leveraged, potential refinancing risk
Interest coverage at -0.2x — earnings do not cover interest payments
Revenue fell 100.0% vs the prior period.
Free cash flow turned negative after being positive in the prior period.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
345
Headquarters
CONCORD, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.